Not an official events of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer® the ASCO Foundation
Monday, June 1, 2026
7:00 p.m. – 8:30 p.m. CT
Please note this virtual program is at 8:00 p.m. Eastern, 7:00 p.m. Central, 6:00 p.m. Mountain and 5:00 p.m. Pacific.
FACULTY
 |
Aman Chauhan, MD Associate Professor of Medicine UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California |
 |
Daniel Morgensztern, MD Professor of Medicine WashU Medicine Washington University St. Louis, Missouri |
PROGRAM OVERVIEW
This educational program is designed to enhance the knowledge and competence of healthcare professionals caring for patients with neuroendocrine lung cancers. It provides an overview of DLL3 biology in small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma of the lung (LCNEC-L), the scientific rationale supporting DLL3 as a target for bispecific T-cell engager (BiTE) therapies, and the mechanism by which these agents redirect T cells. The program also reviews emerging clinical evidence on the efficacy, safety, and dosing of DLL3-targeted BiTEs in extensive-stage SCLC (ES-SCLC) and LCNEC-L, while equipping participants with practical strategies to prevent and manage treatment-related adverse events (TRAEs).
TARGET AUDIENCE
This activity is designed to meet the educational needs of oncologists and oncology advanced practice practitioners (APPs).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify the prevalence of DLL3 overexpression in SCLC and LCNEC-L, the rationale for its suitability as a target for T-cell recognition, and the mechanism of action of DLL3-targeting BiTEs
- Summarize clinical trial efficacy and safety data and recommended dosing for BiTEs that target DLL3 in ES-SCLC and LCNEC-L
- Implement strategies for preventing and mitigating TRAEs
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.5 ANCC contact hours.
AAPA CREDIT DESIGNATION STATEMENT – LIVE
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
